Haemonetics Co. (NYSE:HAE – Get Free Report) hit a new 52-week low on Tuesday . The stock traded as low as $69.25 and last traded at $69.35, with a volume of 603380 shares traded. The stock had previously closed at $71.29.
Analysts Set New Price Targets
HAE has been the topic of several analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $112.00 target price on shares of Haemonetics in a report on Tuesday, December 3rd. JPMorgan Chase & Co. assumed coverage on shares of Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price on the stock. Barrington Research reaffirmed an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a research note on Wednesday, December 4th. Finally, Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective on the stock in a report on Friday, November 8th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Haemonetics currently has a consensus rating of “Moderate Buy” and an average target price of $108.78.
View Our Latest Stock Report on HAE
Haemonetics Trading Down 3.4 %
Haemonetics (NYSE:HAE – Get Free Report) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The company had revenue of $345.50 million for the quarter, compared to the consensus estimate of $342.57 million. During the same quarter last year, the business posted $0.99 EPS. Haemonetics’s quarterly revenue was up 8.6% compared to the same quarter last year. Equities analysts expect that Haemonetics Co. will post 4.59 EPS for the current year.
Institutional Investors Weigh In On Haemonetics
A number of institutional investors have recently modified their holdings of HAE. Global Alpha Capital Management Ltd. acquired a new position in Haemonetics in the third quarter valued at approximately $806,000. Loomis Sayles & Co. L P increased its position in Haemonetics by 8.1% in the third quarter. Loomis Sayles & Co. L P now owns 163,856 shares of the medical instruments supplier’s stock worth $13,171,000 after buying an additional 12,310 shares during the period. BNP Paribas Financial Markets lifted its stake in Haemonetics by 174.5% in the third quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock valued at $1,362,000 after buying an additional 10,774 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of Haemonetics by 10.9% during the third quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier’s stock valued at $66,206,000 after acquiring an additional 80,783 shares during the period. Finally, FMR LLC increased its holdings in shares of Haemonetics by 206.3% in the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock worth $62,257,000 after acquiring an additional 521,640 shares during the period. Institutional investors own 99.67% of the company’s stock.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Recommended Stories
- Five stocks we like better than Haemonetics
- How to Use the MarketBeat Excel Dividend Calculator
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Best Stocks Under $10.00
- What Does the Future Hold for Eli Lilly?
- How to Most Effectively Use the MarketBeat Earnings Screener
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.